These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35148357)

  • 1. Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus-A randomized, placebo-controlled cross-over study.
    Suhrs HE; Nilsson M; Bové KB; Zander M; Prescott E
    PLoS One; 2022; 17(2):e0263481. PubMed ID: 35148357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project).
    Nielsen SF; Duus CL; Buus NH; Bech JN; Mose FH
    JMIR Res Protoc; 2024 May; 13():e56067. PubMed ID: 38680116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
    Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
    Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.
    Jünger C; Prochaska JH; Gori T; Schulz A; Binder H; Daiber A; Koeck T; Rapp S; Lackner KJ; Münzel T; Wild PS
    J Cardiovasc Med (Hagerstown); 2022 Mar; 23(3):191-197. PubMed ID: 34939776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo-controlled double-blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi-center placebo-controlled double-blind randomized trial.
    Tanaka A; Shimabukuro M; Machii N; Teragawa H; Okada Y; Shima KR; Takamura T; Taguchi I; Hisauchi I; Toyoda S; Matsuzawa Y; Tomiyama H; Yamaoka-Tojo M; Ueda S; Higashi Y; Node K
    J Diabetes Investig; 2020 Nov; 11(6):1551-1563. PubMed ID: 32537887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
    Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt-Jacobsen NH; Gæde P; Rossing P; Faber J; Inzucchi SE; Gustafsson F; Kistorp C
    J Am Heart Assoc; 2021 Aug; 10(15):e020418. PubMed ID: 34278803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
    Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
    Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial).
    Jürgens M; Schou M; Hasbak P; Kjær A; Wolsk E; Zerahn B; Wiberg M; Brandt NH; Gæde PH; Rossing P; Faber J; Inzucchi S; Gustafsson F; Kistorp CM
    BMJ Open; 2019 Nov; 9(11):e029098. PubMed ID: 31780586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
    Larsen EL; Cejvanovic V; Kjær LK; Vilsbøll T; Knop FK; Rungby J; Poulsen HE
    BMJ Open; 2017 May; 7(5):e014728. PubMed ID: 28490557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2.
    Huang CH; Huang YY; Hsu BR
    Ann Saudi Med; 2018; 38(6):420-426. PubMed ID: 30531176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
    Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
    Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.
    Assaly R; Gorny D; Compagnie S; Mayoux E; Bernabe J; Alexandre L; Giuliano F; Behr-Roussel D
    J Sex Med; 2018 Sep; 15(9):1224-1234. PubMed ID: 30145094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.